Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

GNPX vs ENTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–1 Matrix Metrics)

ENTX Overall Winner 6-Pillar Tally: GNPX 1 – 3 ENTX (2 Tie) Matrix Metrics: GNPX 1 – 5 ENTX

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas ENTX carries 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. GNPX 42.2/100 HOLD) and 0.92β · 53% Vol risk profile, whereas GNPX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GNPX vs ENTX
GNPX NASDAQ
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -4.68β · 96% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $2.00 · SMA50: $2.48
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap $571.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 53% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 52.0 Fund 49.0 Flow 72.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 61
RSI-14: 61.2 · SMA20: $3.13 · SMA50: $2.93

6-Pillar Scorecard Institutional Category Breakdown (GNPX 1 – 3 ENTX)

Columns: Metric · GNPX · ENTX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale GNPX
Revenue Growth (YoY) +0.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $2.2M $571.2M
3. Profitability & Quality ENTX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -233.7% -20.3%
4. Balance Sheet & Cash Flow ENTX
Cash Generation (TTM) N/A -$16M
Cash Flow Margin N/A N/A
Net Cash / Leverage $11.26 Book/Sh · -233.7% ROE $265M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 116.0% (33rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GNPX (1) vs ENTX (5)
Institutional Metric GNPX ENTX Criterion Row Edge
Market Capitalization
Scale
$2.2M $571.2M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -100.0% Higher Growth GNPX
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-233.7% -20.3% Higher ROE ENTX
52-Week Range Position
Momentum
11% ($0–$10) 73% ($1–$4) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
-4.68β · 96% Vol 0.92β · 53% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 47.5 / 100 (HOLD) Higher Composite ENTX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.26 Book/Sh · -233.7% ROE) -$16M ($265M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTX +36.21 pp
GNPX: -26.77% · ENTX: +9.44%
3M Horizon ENTX +60.57 pp
GNPX: -63.93% · ENTX: -3.36%
6M Horizon ENTX +89.94 pp
GNPX: +76.59% · ENTX: +166.53%
1Y Horizon ENTX +81.31 pp
GNPX: -56.59% · ENTX: +24.72%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GNPX vs ENTX. Trailing 12-month operating profitability (GNPX 0.0% vs ENTX 0.0%) and valuation multiples (GNPX N/M vs ENTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GNPX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-233.7% · N/M
ENTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-20.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GNPX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GNPX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTX CONSOLIDATION
83d in phase · OBV NEUTRAL
Current IV 116.0%
IV Percentile 33rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GNPX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $571.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GNPX vs ENTX Key Questions & Quantitative Answers

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas ENTX carries 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. GNPX 42.2/100 HOLD) and 0.92β · 53% Vol risk profile, whereas GNPX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GNPX leads the Growth & Scale pillar: GNPX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, GNPX generates N/A in USD-normalized revenue versus N/A for ENTX. In operating R&D and SG&A reinvestment, GNPX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.

GNPX and ENTX trade at balanced relative valuation multiples. GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GNPX (-233.7% ROE) versus ENTX (-20.3% ROE) capital efficiency.

In options market volatility and institutional positioning, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk). By comparison, ENTX carries 116.0% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.